Eli Lilly to buy gene-editing biotech Verve Therapeutics Inc. for $1.3 billion

Eli Lilly & Co. agreed to buy Verve Therapeutics Inc., a US biotech that’s seeking to use gene editing to prevent clogged arteries, for as much as $1.3 billion.

US News